O Shaughnessy Asset Management LLC Grows Stock Position in Cencora, Inc. (NYSE:COR)

O Shaughnessy Asset Management LLC boosted its position in shares of Cencora, Inc. (NYSE:COR) by 16.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,965 shares of the company’s stock after buying an additional 7,597 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Cencora were worth $11,900,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. JFS Wealth Advisors LLC grew its holdings in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after purchasing an additional 46 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Cencora during the fourth quarter valued at approximately $30,000. Householder Group Estate & Retirement Specialist LLC grew its stake in shares of Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after buying an additional 69 shares during the last quarter. Kentucky Trust Co purchased a new stake in shares of Cencora in the fourth quarter worth approximately $33,000. Finally, WASHINGTON TRUST Co lifted its stake in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after acquiring an additional 46 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the firm’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the sale, the executive vice president now owns 14,665 shares of the company’s stock, valued at approximately $3,934,326.20. This trade represents a 21.96 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now owns 317,913 shares of the company’s stock, valued at $85,680,732.63. This represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,675 shares of company stock worth $8,034,778. Company insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

COR has been the topic of a number of research analyst reports. Mizuho assumed coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target on the stock. Evercore ISI raised their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Wells Fargo & Company lifted their target price on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. Finally, JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $280.20.

Cencora Trading Up 1.1 %

COR opened at $278.17 on Tuesday. The stock has a market capitalization of $53.94 billion, a PE ratio of 39.57, a P/E/G ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a one year low of $214.77 and a one year high of $280.70. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The business’s 50 day moving average price is $254.53 and its 200 day moving average price is $241.53.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.